IL1B and myocardial infarction: Lastly, in a large clinical study of 10,061 patients with a previous myocardial infarction, treatment with the anti-IL-1β monoclonal antibody, Canakinumab, resulted in reduced myocardial infarctions (Ridker et al., 2017).